Standout Papers

PD-1 Blockade with Nivolumab in Relap... 1996 2026 2006 2016 2.6k
  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (2014)
    Stephen M. Ansell, Alexander M. Lesokhin et al. New England Journal of Medicine
  2. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016)
    Bo Li, Eric A. Severson et al. Genome biology
  3. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK (2009)
    Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology
  4. Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway (1996)
    Marco Antonio Meraz‐Ríos, J. Michael White et al. Cell
  5. Adaptive immunity maintains occult cancer in an equilibrium state (2007)
    Catherine Koebel, William Vermi et al. Nature
  6. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma (2010)
    Michael R. Green, Stefano Monti et al. Blood
  7. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia (2012)
    Steven P. Treon, Lian Xu et al. New England Journal of Medicine
  8. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses (1998)
    Scott J. Rodig, Marco Antonio Meraz‐Ríos et al. Cell
  9. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies (2013)
    Benjamin J. Chen, Bjoern Chapuy et al. Clinical Cancer Research
  10. Tet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells (2011)
    Kian Peng Koh, Akiko Yabuuchi et al. Cell stem cell
  11. Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor (2010)
    James E. Butrynski, David R. D’Adamo et al. New England Journal of Medicine
  12. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome (2016)
    Margaretha G.M. Roemer, Ranjana H. Advani et al. Journal of Clinical Oncology
  13. Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy (2012)
    Michael R. Green, Scott J. Rodig et al. Clinical Cancer Research
  14. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma (2013)
    Bjoern Chapuy, Michael R. McKeown et al. Cancer Cell
  15. Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population (2009)
    Scott J. Rodig, Mari Mino–Kenudson et al. Clinical Cancer Research
  16. Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 (2015)
    Brooke E. Howitt, Sachet A. Shukla et al. JAMA Oncology
  17. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma (2012)
    Loredana Santo, Teru Hideshima et al. Blood
  18. Immunological mechanisms of the antitumor effects of supplemental oxygenation (2015)
    Stephen Hatfield, Jørgen Kjaergäard et al. Science Translational Medicine
  19. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer (2016)
    Kyle C. Strickland, Brooke E. Howitt et al. Oncotarget
  20. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma (2018)
    Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine
  21. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma (2017)
    Suzanne George, Diana Miao et al. Immunity
  22. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma (2017)
    Lakshmi Nayak, Fábio M. Iwamoto et al. Blood
  23. The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007)
    Przemysław Juszczyński, Jing Ouyang et al. Proceedings of the National Academy of Sciences

Immediate Impact

11 by Nobel laureates 62 from Science/Nature 129 standout
Sub-graph 1 of 15

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
SOX17 enables immune evasion of early colorectal adenomas and cancers
2024 StandoutNature
10 intermediate papers

Works of Scott J. Rodig being referenced

Adaptive immunity maintains occult cancer in an equilibrium state
2007 StandoutNature
Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway
1996 Standout
and 8 more

Author Peers

Author Last Decade Papers Cites
Scott J. Rodig 18347 8051 10775 10287 344 33.1k
Ash A. Alizadeh 10763 4617 10355 15023 243 34.2k
Mark Raffeld 13976 10911 7669 6539 423 26.9k
Margaret A. Shipp 13571 12550 7576 5961 207 24.0k
Luis A. Díaz 14224 13891 3523 12867 413 39.4k
Brunangelo Falini 10587 15273 7782 9157 382 32.4k
Louis M. Staudt 9282 10568 11150 15126 285 34.0k
Claudio Doglioni 11430 4642 4163 8469 469 26.2k
Reinhard Dummer 21952 5803 14420 18795 940 43.0k
Kevin C. Gatter 8164 4657 3531 12587 309 26.5k
Robert S. Kerbel 16351 2503 5451 24243 398 41.1k

All Works

Loading papers...

Rankless by CCL
2026